FGF4 and angina pectoris: The transfer of human FGF4 bound to an adenovirus (Ad5-FGF4) vector by intracoronary infusion resulted in increased FGF mRNA production at twelve weeks, enhanced collateral dependent perfusion, and lessened the severity of symptomatic angina in patients in the AGENT trial [32].